Saved in:
| Main Author: | |
|---|---|
| Format: | Recurso digital |
| Language: | |
| Published: |
Zenodo
2026
|
| Online Access: | https://doi.org/10.5281/zenodo.20309579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1866901614618476544 |
|---|---|
| author | Indunil Karunarathna |
| author_facet | Indunil Karunarathna |
| contents | <p class="MsoNormal"><span>Almotriptan is a second-generation serotonin (5-HT) receptor agonist belonging to the triptan class of medications, specifically indicated for the acute treatment of migraine headaches with or without aura in adult and adolescent populations. This article provides a comprehensive overview of almotriptan's clinical pharmacology, including its selective agonism at 5-HT1B and 5-HT1D receptors, which underlies both its therapeutic efficacy in reducing neurogenic inflammation and cranial vasodilation and its potential adverse vascular effects. Key clinical trial data demonstrate that almotriptan 12.5 mg offers an optimal risk-to-benefit ratio, with efficacy comparable to sumatriptan 50 mg but a more favorable side effect profile, particularly regarding chest symptoms. Pharmacokinetically, almotriptan is distinguished from first-generation triptans by higher oral bioavailability (approximately 69%) and a shorter plasma half-life (3 hours), although renal and hepatic impairments necessitate dose adjustments. Contraindications include significant cardiovascular disease, uncontrolled hypertension, cerebrovascular syndromes, hemiplegic or basilar migraine, and concurrent use of ergotamines or other serotonin agonists within 24 hours. Monitoring parameters encompass blood pressure, renal function, and clinical response. While serious toxicity is rare, clinicians should remain vigilant for serotonin syndrome when almotriptan is combined with SSRIs or SNRIs, and caution is advised during pregnancy and lactation due to limited safety data. Optimal outcomes require an interprofessional approach involving neurology, primary care, pharmacy, and nursing, with emphasis on patient education, adherence monitoring, and individualized risk stratification. This activity synthesizes current evidence to equip healthcare professionals with the practical knowledge necessary for safe and effective almotriptan prescribing.</span></p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_20309579 |
| institution | Zenodo |
| language | |
| publishDate | 2026 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Almotriptan in the Acute Management of Migraine: A Pharmacological and Clinical Overview for the Interprofessional Team Indunil Karunarathna <p class="MsoNormal"><span>Almotriptan is a second-generation serotonin (5-HT) receptor agonist belonging to the triptan class of medications, specifically indicated for the acute treatment of migraine headaches with or without aura in adult and adolescent populations. This article provides a comprehensive overview of almotriptan's clinical pharmacology, including its selective agonism at 5-HT1B and 5-HT1D receptors, which underlies both its therapeutic efficacy in reducing neurogenic inflammation and cranial vasodilation and its potential adverse vascular effects. Key clinical trial data demonstrate that almotriptan 12.5 mg offers an optimal risk-to-benefit ratio, with efficacy comparable to sumatriptan 50 mg but a more favorable side effect profile, particularly regarding chest symptoms. Pharmacokinetically, almotriptan is distinguished from first-generation triptans by higher oral bioavailability (approximately 69%) and a shorter plasma half-life (3 hours), although renal and hepatic impairments necessitate dose adjustments. Contraindications include significant cardiovascular disease, uncontrolled hypertension, cerebrovascular syndromes, hemiplegic or basilar migraine, and concurrent use of ergotamines or other serotonin agonists within 24 hours. Monitoring parameters encompass blood pressure, renal function, and clinical response. While serious toxicity is rare, clinicians should remain vigilant for serotonin syndrome when almotriptan is combined with SSRIs or SNRIs, and caution is advised during pregnancy and lactation due to limited safety data. Optimal outcomes require an interprofessional approach involving neurology, primary care, pharmacy, and nursing, with emphasis on patient education, adherence monitoring, and individualized risk stratification. This activity synthesizes current evidence to equip healthcare professionals with the practical knowledge necessary for safe and effective almotriptan prescribing.</span></p> |
| title | Almotriptan in the Acute Management of Migraine: A Pharmacological and Clinical Overview for the Interprofessional Team |
| url | https://doi.org/10.5281/zenodo.20309579 |